Entera Bio Ltd. (ENTX)

NASDAQ: ENTX · IEX Real-Time Price · USD
1.16
-0.06 (-4.92%)
At close: Mar 31, 2023, 4:00 PM
1.14
-0.02 (-1.72%)
After-hours: Mar 31, 2023, 7:22 PM EDT
-4.92%
Market Cap 33.42M
Revenue (ttm) 134,000
Net Income (ttm) -13.07M
Shares Out 28.81M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 66,039
Open 1.17
Previous Close 1.22
Day's Range 1.11 - 1.23
52-Week Range 0.47 - 3.00
Beta 1.80
Analysts Buy
Price Target 5.78 (+398.28%)
Earnings Date May 10, 2023

About ENTX

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreeme... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 28, 2018
Employees 19
Stock Exchange NASDAQ
Ticker Symbol ENTX
Full Company Profile

Financial Performance

In 2022, Entera Bio's revenue was $134,000, a decrease of -76.53% compared to the previous year's $571,000. Losses were -$13.07 million, 7.25% more than in 2021.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ENTX stock is "Buy." The 12-month stock price forecast is $5.78, which is an increase of 398.28% from the latest price.

Price Target
$5.78
(398.28% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates

Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 16.67% and 86%, respectively, for the quarter ended December 2022.

12 hours ago - Zacks Investment Research

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

JERUSALEM, March 31, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today annou...

15 hours ago - GlobeNewsWire

Entera Bio Regains Compliance with Nasdaq Listing Requirements

JERUSALEM, March 23, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced t...

1 week ago - GlobeNewsWire

Entera Bio Announces FDA's Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

JERUSALEM, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announ...

1 month ago - GlobeNewsWire

Entera Bio to Participate in the SVB Securities Global Biopharma Conference

JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a late-clinical stage, leader in the development of orally delivered peptides and therapeutic p...

1 month ago - GlobeNewsWire

Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know

Entera Bio Ltd. (ENTX) closed at $0.95 in the latest trading session, marking no change from the prior day.

2 months ago - Zacks Investment Research

Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know

In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.95, marking no change from the previous day.

2 months ago - Zacks Investment Research

New Strong Buy Stocks for December 29th

SPNS, CRS, DHT, DCBO and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on December 29, 2022.

Other symbols: CRSDCBODHTSPNS
3 months ago - Zacks Investment Research

New Strong Buy Stocks for November 21st

AMRK, ACR, EDAP, H and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2022.

Other symbols: ACRAMRKEDAPH
4 months ago - Zacks Investment Research

New Strong Buy Stocks for November 16th

ENTX, STIM, FN, ANGN and FUTU have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2022.

Other symbols: ANGNFNFUTUSTIM
4 months ago - Zacks Investment Research

Entera Bio Ltd. (ENTX) Reports Q3 Loss, Misses Revenue Estimates

Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 31.25% and 88.57%, respectively, for the quarter ended September 2022.

5 months ago - Zacks Investment Research

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announ...

5 months ago - GlobeNewsWire

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

- Total Hip BMD Established as Primary Endpoint - - Total Hip BMD Established as Primary Endpoint -

6 months ago - GlobeNewsWire

Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613's Potential Impact on Wednesday, September 28th @ 10am ET

JERUSALEM, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today anno...

6 months ago - GlobeNewsWire

Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today annou...

7 months ago - GlobeNewsWire

Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today annou...

7 months ago - GlobeNewsWire

Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announ...

8 months ago - GlobeNewsWire

Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting

JERUSALEM, July 26, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announ...

8 months ago - GlobeNewsWire

Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO

Following its End of Phase 2 Meeting with the FDA, Entera Bio Ltd (NASDAQ: ENTX) has designed the pivotal study for EB613 as an 18-month double-blind placebo-controlled study, followed by a 6-month op...

9 months ago - Benzinga

Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the fol...

9 months ago - GlobeNewsWire

Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company's President of Research & Development to Pursue Outside Opportunities

BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Dr. Phil...

10 months ago - GlobeNewsWire

Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

BOSTON and JERUSALEM, May 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its financial and op...

11 months ago - GlobeNewsWire

Follow the Insiders and Buy the Dip in These 3 Stocks

These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.

Other symbols: LGVNTCON
11 months ago - InvestorPlace

Recession Fears are Creating a Golden Opportunity for Biotech Stocks

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech S...

1 year ago - InvestorPlace

Entera Bio Reports Financial Results for the Year Ended December 31, 2021

— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 — — New EB612 formulation for Hypoparathyroidism trial planned in 2022 — — Oral delivery technology platform advances with more ...

1 year ago - GlobeNewsWire